Pharmacy POS in Southeast Asia: the generic-name rule most tills ignore

By Priya Nair · Updated August 15, 2026 · 11 min read · Practical guide · Southeast Asia

A customer puts a prescription on your counter. You know the brand, you know you are out of it, and you are fairly sure there is something on the shelf with the same active substance under a different name at a different price. In the Philippines, telling them about it is not a courtesy. It is written into the Generics Act. And here is the awkward part: the till in front of you almost certainly cannot answer the question. This guide walks through what a drugstore in the region actually needs from its software, starting with the one thing the brochures never mention.

What the law actually asks of a drug outlet

Start with the text, because it is more demanding than most owners remember. Section 6 of Republic Act 6675, the Generics Act of 1988, says that drug outlets, "including drugstores, hospital and non-hospital pharmacies and non-traditional outlets such as supermarkets and stores, shall inform any buyer about any and all other drug products having the same generic name, together with their corresponding prices so that the buyer may adequately exercise, his option".

Read that again. Not "may mention". Not "if asked". Any and all other products with the same generic name, with their prices. The same section adds a second duty that is easy to forget: outlets must post, in a conspicuous place in the establishment, a list of drug products carrying the same generic name together with their corresponding prices.

Section 12 puts teeth behind it. For individuals, violations of Section 6 run from a reprimand for a first offence, to a fine of P2,000 to P5,000 for a second, P5,000 to P10,000 plus a 30-day suspension for a third, and P10,000 or more with a one-year suspension after that. Organisations face fines and the possible suspension or revocation of their licence. You can read the full text of RA 6675 yourself, and you should, because enforcement practice and implementing rules move even when the statute does not.

The same logic exists in different forms elsewhere in the region, where generic prescribing and price transparency have been policy priorities for years. The wording differs country by country, so check your own regulator rather than assuming the Philippine rule travels.

Generic name, INN: the only name you can trust

The generic name is not a marketing category. It is the name of the active substance, assigned by the World Health Organization through its International Nonproprietary Names programme. WHO puts it plainly: each INN is a unique name that is globally recognised and is public property.

That last part is what makes it useful behind a counter. Because the name belongs to nobody, it is the same in Manila, Jakarta and Hanoi, on a local box and an imported one. Two products with wildly different packaging and a threefold price gap can carry the same INN. Brand names cannot tell you that. Barcodes cannot tell you that. Only the molecule can.

Why your till can't answer "what else has this molecule?"

General retail software models a product as three things: a name, a barcode and a price. That is enough for a hardware store. A pharmacy needs a fourth and fifth: the active substance, and its strength and form. If those fields do not exist in the catalogue, no search box will ever surface an equivalent, however good the interface looks.

So the question to put to any vendor is narrow and easy to test. On my own stock, not your demo data: can you type a molecule and show me everything I hold under it, with strength, form, quantity on hand and price, side by side? Everything else in the demo can wait until they have answered that.

What good looks like at the counter:

1. Search by molecule as easily as by brand. One field, both work.
2. Equivalents surfacing on their own when the requested item hits zero, with real quantity on hand.
3. Strength and form shown, because 500 mg tablets and 125 mg syrup are not interchangeable answers to one prescription.
4. Prices side by side, which is both what the buyer wants and, in the Philippines, what Section 6 asks you to provide.

Batches and expiry: FEFO, not FIFO

Plenty of stock tools do FIFO: first in, first out. For medicines that is not enough. What matters is FEFO, first expired, first out. The difference sounds academic until you destroy a box received eight months ago while an older box with a longer shelf life sits quietly beside it.

FEFO needs the system to think in batches, not just products. Every goods-in records a batch number and an expiry date, every sale proposes the batch closest to expiry first, and alerts arrive early enough that you can still sell the stock rather than write it off.

The practical bottleneck is data entry. Most medicine packs now carry a two-dimensional Data Matrix code holding the product identifier, the batch number and the expiry date together. Software that reads all three in one scan spares your staff the manual batch entry that everybody quietly skips once a queue forms. And a batch entered wrongly makes FEFO worthless.

Stock that only knows quantities tells you what is left. Stock that knows batches tells you what you are about to lose, and when.

The product catalogue question

Ask early where the product database comes from. If you have to create every reference yourself, with its molecule, strength and form, you will not do it. Nobody does. Three weeks in, the catalogue is half empty, molecule search returns nothing, and everyone goes back to walking the shelves from memory.

Software that ships with a medicine catalogue already built on public drug databases starts out knowing the molecules. That is the difference between a feature you use on day one and a feature you plan to configure some day. Ask each vendor which databases their catalogue is built on, how many references it holds, and how often it is refreshed.

The rest of the counter: patients, staff, blackouts

A community drugstore runs on relationships. Patient records keep the dispensing history that makes refills quick and awkward questions unnecessary. Customer credit lets you record a sale as owed rather than keeping a separate notebook, which matters in neighbourhoods where people settle up on payday.

Staff controls matter for a different reason. Individual PIN access rather than one shared login tells you who did what, and a cap on the discount an assistant can give without approval prevents the slow leak that nobody notices until the margin review. We cover that pattern in detail in our guide to customer tabs and staff discount limits.

Then there is power and connectivity. In much of the region a brownout is a scheduling matter, not a surprise. Most cloud tills keep selling offline, which is table stakes. The real question is what else survives: can you still look up stock, search a molecule, see batches and dates? Test it before you buy. Turn off mobile data and Wi-Fi, then try a sale, a name search, a molecule search, a stock lookup and a receipt print. Whatever fails in that five-minute test will fail on the day it counts.

Where the tax side fits

Registering a till with the Bureau of Internal Revenue is a separate exercise from choosing your software, and the requirements have changed more than once in recent years. Do not let a vendor blur the two. What your software owes you is a clean, exportable sales base and the invoice and report formats the tax office expects. The compliance step itself is yours, and the only reliable answer comes from the BIR. We walk through the current landscape in our guide to a BIR-accredited POS in the Philippines.

Two more licences sit behind the counter and have nothing to do with software, but they gate everything else: the FDA licence to operate for the outlet, and a pharmacist licensed by the Professional Regulation Commission. Without the second, the first is academic.

The options on the table

Broadly you are choosing between three families: purpose-built pharmacy software, a general cloud POS, and something that tries to cover both. Here is how we rank them for a community drugstore, with the caveat that features and prices move and every claim below deserves a live demo on your own stock.

At a glance

Compiled from public vendor documentation reviewed in August 2026 and features confirmed by the vendors. "Ask for a demo" does not mean absent: it means we could not confirm it publicly and you should have it shown to you. Verify on your own catalogue before committing.

Frequently asked questions

Official sources

This is regulated ground, so check it yourself rather than taking our word for it.

• Republic Act No. 6675, the Generics Act of 1988: full statutory text, including the Section 6 duties of drug outlets and the Section 12 penalties.
• World Health Organization, International Nonproprietary Names programme: what an INN is, who assigns it and why it is public property.
• Professional Regulation Commission: licensing of pharmacists in the Philippines.